134 related articles for article (PubMed ID: 35022206)
1. Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Lim SM; Kim CG; Lee JB; Cho BC
Cancer Discov; 2022 Jan; 12(1):16-19. PubMed ID: 35022206
[TBL] [Abstract][Full Text] [Related]
2. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.
Lim SM; Kim CG; Cho BC
Cancer Res; 2022 Jan; 82(1):18-20. PubMed ID: 34983785
[TBL] [Abstract][Full Text] [Related]
5. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
[TBL] [Abstract][Full Text] [Related]
6. Patritumab deruxtecan shows activity in EGFR-mutant NSCLC.
Sidaway P
Nat Rev Clin Oncol; 2023 Dec; 20(12):817. PubMed ID: 37749383
[No Abstract] [Full Text] [Related]
7. Targeting HER3 to overcome EGFR TKI resistance in NSCLC.
Chen Q; Jia G; Zhang X; Ma W
Front Immunol; 2023; 14():1332057. PubMed ID: 38239350
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
[TBL] [Abstract][Full Text] [Related]
9. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
10. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
12. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Desai S; Kim C; Veytsman I
Curr Oncol Rep; 2019 Aug; 21(9):84. PubMed ID: 31410582
[TBL] [Abstract][Full Text] [Related]
13. Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.
Pacheco JM
Cancer Discov; 2021 Jul; 11(7):1617-1619. PubMed ID: 34284994
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
17. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
Linardou H; Dahabreh IJ; Bafaloukos D; Kosmidis P; Murray S
Nat Rev Clin Oncol; 2009 Jun; 6(6):352-66. PubMed ID: 19483740
[TBL] [Abstract][Full Text] [Related]
18. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
19. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
[TBL] [Abstract][Full Text] [Related]
20. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]